|
Jul 24
|
Despite shrinking by US$346m in the past week, Ascendis Pharma (NASDAQ:ASND) shareholders are still up 54% over 1 year
|
|
Jun 24
|
Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024
|
|
Jun 21
|
Ascendis Pharma A/S (ASND) Stock Soared on Unexpected Demand
|
|
May 15
|
FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
|
|
May 15
|
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
|
|
May 14
|
US Equity Markets Close Higher Tuesday as Producer Prices Rise
|
|
May 14
|
UPDATE 2-US FDA extends review of Ascendis Pharma's hormone disorder therapy
|
|
May 14
|
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism
|
|
May 13
|
Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial
|
|
Feb 10
|
US$172 - That's What Analysts Think Ascendis Pharma A/S (NASDAQ:ASND) Is Worth After These Results
|
|
Feb 8
|
Ascendis Pharma A/S (NASDAQ:ASND) Q4 2023 Earnings Call Transcript
|
|
Feb 7
|
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
|
|
Feb 7
|
Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
|
|
Jan 10
|
Investors ignore increasing losses at Ascendis Pharma (NASDAQ:ASND) as stock jumps 11% this past week
|
|
Dec 28
|
Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 20
|
Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon™ CNP (Navepegritide) at 100 µg/kg/week
|
|
Dec 19
|
TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency
|
|
Nov 29
|
Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan
|
|
Oct 16
|
Ascendis Pharma Presents TransCon™ PTH (palopegteriparatide) Phase 3 52-Week Skeletal Dynamics Data at ASBMR 2023
|
|
Sep 5
|
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
|